objective To compare two commercially available kits, Japanese Encephalitis-Dengue IgM Combo ELISA (Panbio Diagnostics) and JEV-CheX IgM capture ELISA (XCyton Diagnostics Limited), to a reference standard (Universiti Malaysia Sarawak -Venture Technologies VT ELISA).
Introduction
Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus; it is the leading cause of encephalitis in Southeast Asia. Over 3 billion people live in areas where Japanese encephalitis (JE) is endemic; it causes an estimated 20 000-175 000 cases annually with 6000-15 000 deaths (Tsai 2000; Halstead & Tsai 2004; Ghosh & Basu 2009) . The virus continues to spread into new areas and often co-circulates with the related flavivirus, dengue.
Affordable vaccines are now becoming available, but implementation programmes are hampered because the epidemiological data and surveillance for JE are poor; this is largely because of lack of standardised diagnostics. JE is endemic in resource-poor areas and in these settings; patients often have a clinical diagnosis only. Serological tests are the gold standard for diagnosis of JEV as the period of viraemia is short, making methods to detect genomic material or viral antigen unreliable (WHO 2006) . The timing of sample collection and type of sample collected impact on the ability to confirm the diagnosis of JEV. Cerebrospinal fluid (CSF) is the sample of choice, as detection of antibodies in the CSF confirms viral infection of the central nervous system (CNS). Serum samples demonstrate recent peripheral infection only. Even demonstrating a rising serum IgM is insufficient for confirmation of JEV as the causative agent for an acute encephalitis syndrome (AES), as this does not distinguish peripheral from CNS infection. Studies from Thailand suggest that high titres of JEV IgM may be found in sera of asymptomatic individuals (Grossman et al. 1973) . Burke et al. (1985) found that by day 7 of illness, 100% of patients 
